Epoetin beta (NeoRecormon®) corrects anaemia in patients with hormone-refractory prostate cancer and bone metastases

Anticancer Research

Volumn 24, Issue 3 B, 2004, Pages 1957-1961

  Bogdanos, J ^a,b   Karamanolakis, D ^a,b   Milathianakis, K ^a,b   Repousis, P ^b   Chloraki Bobota, A ^b   Majed, H ^b   Pagalou Thoua, E ^b   Tsintavis, A ^b   Koutsilieris, Michael ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b METAXA CANCER HOSPITAL   (Greece)

Author keywords

Anaemia; Epoetin beta; Hormone refractory prostate cancer; Metastatic prostate cancer

Indexed keywords

IRON; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; BONE METASTASIS; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; EVALUATION; HEMOGLOBIN DETERMINATION; HUMAN; IRON THERAPY; MALE; OPEN STUDY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

AGED; ANEMIA; ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HEMOGLOBINS; HUMANS; MALE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS;

EID: 3242711493     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Mercadante S, Gebbia V, Marrazo A and Filostos S: Anemia in cancer: pathophysiology and treatment. Cancer Treat Rev 26: 303-311, 2000.
2. Henry DH: Recombinant human erythropoietin in the treatment of anemia associated with solid tumors. In: (Bauer C, Koch KM, Scigalla, P, Wieczorek L, eds) Erythropoietin: Molecular Physiology and Clinical Applications. New York: Marcel Dekker, 1993, pp 293-298.
3. Ornstein DK, Beiser JA and Andriole GL: Anaemia in men receiving combined finasteride and flutamide therapy for advanced prostate cancer. BJU Int 83: 43-46, 1999.
4. Strum SB, McDermed JE, Scholz MC, Johnson H and Tisman G: Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 79: 933-941, 1997.
5. Geenen RW, Delaere KP and van Wersch JW: Haematological variables in prostatic carcinoma patients. Acta Urol Belg 64: 21-26, 1996.
6. Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, Portelance L, Crook J and Jones KD: The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86: 1528-1536, 1999.
7. Caro JJ, Salas M, Ward A and Goss G: Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91: 2214-2221, 2001.
8. Ludwig H and Strasser K: Symptomatology of anemia. Semin Oncol 28: 7-14, 2001.
9. Demetri GD: Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br J Cancer 84 (Suppl 1): 31-37, 2001.
10. Lyman GH, Berndt E, Crown W, Kallich J, Erder H and Finkelstein S: Anemia is associated with high cost in newly diagnosed cancer patients. Blood 98 (Part 2): 414b, 2001.
11. Österborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M and Messinger D for the Epoetin Beta Hematology Study Group: Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 20: 2486-2494, 2002.
12. Glimelius B, Linne T, Hoffman K, Larsson L, Svensson JH, Nasman P, Svensson B and Helmers C: Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer. J Clin Oncol 16: 434-440, 1998.
13. Littlewood TJ, Bajetta E, Nortier J, Vercammen E and Rapoport B: Effects of epoetin-α on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind placebo-controlled trial. J Clin Oncol 19: 2865-2874, 2001.
14. Johansson JE, Wersall P, Brandberg Y, Andersson SO and Nordstrom L and the EPO-Study Group: Efficacy of epoetin beta on hemoglobin, QoL, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer. A randomized study. Scand J Urol Nephrol 35: 288-294, 2001.
15. Beshara S, Letocha H, Linde T, Wikstrom B, Sandhagen B, Nilsson S and Danielson BG: Anemia associated with advanced prostatic adenocarcinoma: effects of recombinant human erythropoietin. Prostate 31: 153-160, 1997.
16. Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler L, Essers U, Greil R, Grossi A and Jager G: Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 86: 4446-4453, 1995.
17. Smith JA Jr, Soloway MS and Young MJ: Complications of advanced prostate cancer. Urology 54 (Suppl): 8-14, 1999.
18. Modder B, Foley JE and Fisher JW: The in vitro and in vivo effects of testosterone and steroid metabolites on erythroid colony forming cells (CFU-E). J Pharmacol Exp Ther 207: 1004-1012, 1978.
19. Cazzola M, Beguin Y, Kloczko J, Spicka I and Coiffier B: Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin deficiency. Br J Haematol 122: 386-393, 2003.
20. Bogdanos J, Karamanolakis D, Milathianakis C, Repousis P, Tsintavis A and Koutsilieris M: Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement. Anticancer Res 23: 1757-1762, 2003.